Covalent inhibitors:A rational approach to drug discovery

Covalent inhibitors are recognized as an important component in drug discovery and therapeutics. Since the first appearance of covalent inhibitors in the late 18th century, the field has advanced significantly and currently about 30% of the marketed drugs are covalent inhibitors. The numerous advantages of covalent inhibitors are counteracting the initial concerns regarding potential off-target toxicity. Thus, continuous research, especially for cancer targets is reported. The aim of this review is to provide a short historic overview and focus on recently developed covalent inhibitors (2011-2019), including structural aspects and examples on challenging targets

Multicomponent Reactions and Their Libraries - a New Approach to Preparative Organic Chemistry

Classical chemical syntheses from n starting materials usually require sequences of at least n-I preparation steps, including separation and purification of the intermediates. A perfect alternative for the rapid syntheses of a large variety of agrichemically and pharmaceutically relevant products are one-pot syntheses by multicomponent reactions (MCR)on the basis of isocyanides. Four to seven different types of components mixed in a reaction vessel undergo the transformation to one molecule. Due to the last irreversible step that involves the isocyanides, a stable product results in quantitative yields. Using more than one representative of each type of starting materials (i.e. different isocyanides, amines, etc.) in the same vessel, all possible combinations will lead to a molecular library with hundreds and thousands of products formed according to a given reaction scheme. The design of such syntheses and the handling of the results require adequate mathematics and computer tools

Update on targeted cancer therapies, single or in combination, and their fine tuning for precision medicine

Background: Until recently, patients who have the same type and stage of cancer all receive the same treatment. It has been established, however, that individuals with the same disease respond differently to the same therapy. Further, each tumor undergoes genetic changes that cause cancer to grow and metastasize. The changes that occur in one person's cancer may not occur in others with the same cancer type. These differences also lead to different responses to treatment. Precision medicine, also known as personalized medicine, is a strategy that allows the selection of a treatment based on the patient's genetic makeup. In the case of cancer, the treatment is tailored to take into account the genetic changes that may occur in an individual's tumor. Precision medicine, therefore, could be defined in terms of the targets involved in targeted therapy. Methods: A literature search in electronic data bases using keywords “cancer targeted therapy, personalized medicine and cancer combination therapies” was conducted to include papers from 2010 to June 2019. Results: Recent developments in strategies of targeted cancer therapy were reported. Specifically, on the two types of targeted therapy; first, immune-based therapy such as the use of immune checkpoint inhibitors (ICIs), immune cytokines, tumor-targeted superantigens (TTS) and ligand targeted therapeutics (LTTs). The second strategy deals with enzyme/small molecules-based therapies, such as the use of a proteolysis targeting chimera (PROTAC), antibody-drug conjugates (ADC) and antibody-directed enzyme prodrug therapy (ADEPT). The precise targeting of the drug to the gene or protein under attack was also investigated, in other words, how precision medicine can be used to tailor treatments. Conclusion: The conventional therapeutic paradigm for cancer and other diseases has focused on a single type of intervention for all patients. However, a large literature in oncology supports the therapeutic benefits of a precision medicine approach to therapy as well as combination therapies

Strategies for the production of long-acting therapeutics and efficient drug delivery for cancer treatment

Protein therapeutics play a significant role in treating many diseases. They, however, suffer from patient's proteases degradation and antibody neutralization which lead to short plasma half-lives. One of the ways to overcome these pitfalls is the frequent injection of the drug albeit at the cost of patient compliance which affects the quality of life of patients. There are several techniques available to extend the half-life of therapeutics. Two of the most common protocols are PEGylation and fusion with human serum albumin. These two techniques improve stability, reduce immunogenicity, and increase drug resistance to proteases. These factors lead to the reduction of injection frequency which increases patient compliance and improve quality of life. Both techniques have already been used in many FDA approved drugs. This review describes many technologies to produce long-acting drugs with the attention of PEGylation and the genetic fusion with human serum albumin. The report also discusses the latest modified therapeutics in the field and their application in cancer therapy. We compare the modification methods and discuss the pitfalls of these modified drugs

1-[(3-Chloro­phen­yl)(morpholin-4-yl)­meth­yl]naphthalen-2-ol

In the title compound, C21H20ClNO2, the dihedral angle between the naphthyl­ene ring system and the phenyl ring is 77.86 (15)°. The morpholine ring adopts a chair conformation. The hydroxyl group is involved in intra­molecular O—H⋯N hydrogen bonding. A weak inter­molecular C—H⋯π inter­action is present in the crystal structure

1-{Phen­yl[1-(p-tol­yl)ethyl­amino]meth­yl}-2-naphthol

The title compound, C26H25NO, was obtained via a one-pot synthesis from the reaction of 2-naphthol, 1-(p-tol­yl)ethyl­amine, p-toluene­sulfonic acid and benzaldehyde. There are three mol­ecules per asymmetric unit, all having similar conformations. There are intra­molecular O—H⋯N and C—H⋯O hydrogen bonds, with only van der Waals forces found between mol­ecules

Impact of Moderate Physical Activity on Inflammatory Markers and Telomere Length in Sedentary and Moderately Active Individuals with Varied Insulin Sensitivity

Introduction: Physical activity-associated immune response plays a crucial role in the aging process. This study aimed to determine the impact of short-term moderate physical activity on cytokine levels, oxidative stress markers, and telomere length in lean/ overweight young subjects. Methods: Fasting blood samples were collected from 368 participants at Qatar Biobank. Based on their homeostatic model assessment of insulin resistance (HOMA-IR), participants were categorized as insulin sensitive (IS) or insulin resistant (IR). Subsequently, they were divided into four groups: sedentary IS (n = 90), sedentary IR (n = 90), moderately active IS (n = 94), and moderately active IR (n = 94). Moderate physical activity was defined as walking at least two days per week for more than 150 minutes, as determined by physical activity questionnaires. Serum samples were analyzed for circulating inflammatory cytokines (IL-1β, IL-1RA, IL-6, IL-10, IL-22, MCP-1/CCL2, TNF-α), as well as antioxidant enzyme levels (SOD and catalase). Telomere lengths were measured in the respective DNA samples. Results: Moderately active IR participants exhibited significantly lower SOD activity, while catalase activity did not show significant differences. Moderately active IS participants had higher IL-6 and IL-10 levels compared to sedentary IS participants, with no significant differences observed in the IR counterparts. Telomere length did not significantly differ between the physically active and sedentary groups. Conclusion: This study highlights the potential anti-inflammatory and anti-oxidative stress effects of moderate physical activity in individuals with insulin sensitivity and insulin resistance. However, no significant changes in telomere length were observed, suggesting a complex relationship between physical activity and the aging process. Further research is needed to fully understand the underlying mechanisms and optimize the balance between anti-inflammation and anti-oxidation through exercise and lifestyle adjustments.</p

4-[(2-Hy­droxy­naphthalen-1-yl)(morpholin-4-yl)meth­yl]benzonitrile

The title compound, C22H20N2O2, was synthesized via a multicomponent reaction using naphthalen-2-ol, morpholine and 4-formyl­benzonitrile. The dihedral angle between the naphthalene ring system and the benzene ring is 81.25 (10)°. The morpholine ring adopts a chair conformation. The mol­ecular conformation is stabilized by intra­molecular O—H⋯N and C—H⋯O hydrogen bonds. In the crystal, inter­molecular C—H⋯N hydrogen bonds link mol­ecules into helical chains running parallel to the c axis